Prognostic significance of longitudinal strain in dilated cardiomyopathy with recovered ejection fraction.


Journal

Heart (British Cardiac Society)
ISSN: 1468-201X
Titre abrégé: Heart
Pays: England
ID NLM: 9602087

Informations de publication

Date de publication:
05 2022
Historique:
received: 25 04 2021
accepted: 12 08 2021
pubmed: 9 9 2021
medline: 13 4 2022
entrez: 8 9 2021
Statut: ppublish

Résumé

Patients with non-ischaemic dilated cardiomyopathy (NICM) may experience a normalisation in left ventricular ejection fraction (LVEF). Although this correlates with improved prognosis, it does not correspond to a normalisation in the risk of death during follow-up. Currently, there are no tools to risk stratify this population. We tested the hypothesis that absolute global longitudinal strain (aGLS) is associated with mortality in patients with NICM and recovered ejection fraction (LVEF). We designed a retrospective, international, longitudinal cohort study enrolling patients with NICM with LVEF <40% improved to the normal range (>50%). We studied the relationship between aGLS measured at the time of the first recording of a normalised LVEF and all-cause mortality during follow-up. We considered aGLS >18% as normal and aGLS ≥16% as of potential prognostic value. 206 patients met inclusion criteria. Median age was 53.5 years (IQR 44.3-62.8) and 56.6% were males. LVEF at diagnosis was 32.0% (IQR 24.0-38.8). LVEF at the time of recovery was 55.0% (IQR 51.7-60.0). aGLS at the time of LVEF recovery was 13.6%±3.9%. 166 (80%) and 141 (68%) patients had aGLS ≤18% and <16%, respectively. During a follow-up of 5.5±2.8 years, 35 patients (17%) died. aGLS at the time of first recording of a recovered LVEF correlated with mortality during follow-up (HR 0.90, 95% CI 0.91 to 0.99, p=0.048 in adjusted Cox model). No deaths were observed in patients with normal aGLS (>18%). In unadjusted Kaplan-Meier survival analysis, aGLS <16% was associated with higher mortality during follow-up (31 deaths (22%) in patients with GLS <16% vs 4 deaths (6.2%) in patients with GLS ≥16%, HR 3.2, 95% CI 1.1 to 9, p=0.03). In patients with NICM and normalised LVEF, an impaired aGLS at the time of LVEF recovery is frequent and associated with worse outcomes.

Identifiants

pubmed: 34493546
pii: heartjnl-2021-319504
doi: 10.1136/heartjnl-2021-319504
pmc: PMC8898986
mid: NIHMS1736340
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

710-716

Subventions

Organisme : NHLBI NIH HHS
ID : K08 HL145108
Pays : United States

Informations de copyright

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Can J Cardiol. 2009 May;25(5):e147-50
pubmed: 19417864
J Card Fail. 2004 Jun;10(3):250-7
pubmed: 15190536
Lancet. 2019 Jan 5;393(10166):61-73
pubmed: 30429050
J Am Soc Echocardiogr. 2012 Jul;25(7):726-32
pubmed: 22537395
J Am Coll Cardiol. 2002 Jan 16;39(2):210-8
pubmed: 11788209
J Am Coll Cardiol. 2003 Aug 20;42(4):736-42
pubmed: 12932612
J Am Coll Cardiol. 2018 Sep 25;72(13):1557-1558
pubmed: 30236318
J Am Heart Assoc. 2015 Jan 13;4(1):e001504
pubmed: 25587018
Am Heart J. 2014 Nov;168(5):721-30
pubmed: 25440801
Heart. 2017 May;103(9):679-686
pubmed: 27799316
Circ Heart Fail. 2017 Jun;10(6):
pubmed: 28559418
Eur J Heart Fail. 2018 Feb;20(2):228-239
pubmed: 29271570
J Am Coll Cardiol. 2012 Dec 18;60(24):2465-72
pubmed: 23158527
Int J Cardiol Heart Vasc. 2018 Mar 08;18:52-57
pubmed: 29876504
J Am Coll Cardiol. 2017 Feb 28;69(8):1043-1056
pubmed: 28231932
Eur Heart J. 2016 Jun 14;37(23):1850-8
pubmed: 26792875
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
J Am Coll Cardiol. 2013 Jan 8;61(1):77-84
pubmed: 23199515
Eur J Heart Fail. 2020 Jul;22(7):1111-1121
pubmed: 32452075
JACC Cardiovasc Imaging. 2018 Aug;11(8):1196-1201
pubmed: 30092974
J Am Heart Assoc. 2018 Oct 16;7(20):e09841
pubmed: 30371257
J Am Soc Echocardiogr. 2019 Nov;32(11):1396-1406.e2
pubmed: 31679581
Heart. 2014 Nov;100(21):1673-80
pubmed: 24860005
JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 1):167-169
pubmed: 31481298
Cardiovasc Ther. 2012 Jun;30(3):172-81
pubmed: 21108773
Circulation. 2014 Jun 10;129(23):2380-7
pubmed: 24799515
J Am Soc Echocardiogr. 2019 Jan;32(1):1-64
pubmed: 30282592
Eur Heart J. 2016 Apr 14;37(15):1196-207
pubmed: 26508168

Auteurs

Marco Merlo (M)

Cardiology Unit, Cardiothoracovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy.

Marco Masè (M)

Cardiology Unit, Cardiothoracovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy.

Andrew Perry (A)

Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.

Eluisa La Franca (E)

Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, IRCCS-ISMETT, Palermo, Italy.

Elena Deych (E)

Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.

Laura Ajello (L)

Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, IRCCS-ISMETT, Palermo, Italy.

Diego Bellavia (D)

Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, IRCCS-ISMETT, Palermo, Italy.

Andrea Boscutti (A)

Cardiology Unit, Cardiothoracovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy.

Marco Gobbo (M)

Cardiology Unit, Cardiothoracovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy.

Giuseppe Romano (G)

Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, IRCCS-ISMETT, Palermo, Italy.

Davide Stolfo (D)

Cardiology Unit, Cardiothoracovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy.

John Gorcsan (J)

Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.

Francesco Clemenza (F)

Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, IRCCS-ISMETT, Palermo, Italy.

Gianfranco Sinagra (G)

Cardiology Unit, Cardiothoracovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy.

Luigi Adamo (L)

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA ladamo2@jhmi.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH